Quantum Biopharma (NASDAQ:QNTM) Stock Lifted to “Hold” by Wall Street Zen

Wall Street Zen upgraded shares of Quantum Biopharma (NASDAQ:QNTM – Free Report) from a sell rating to a hold rating in a research report report published on Saturday morning,Wall Street Zen reports.

QNTM has been the subject of a number of other reports. Rodman & Renshaw initiated coverage on shares of Quantum Biopharma in a research note on Monday, August 31st. They set a “buy” rating and a $8.00 price objective for the company. Weiss Ratings cut shares of Quantum Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, November 2nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Quantum Biopharma currently has an average rating of “Hold” and an average price target of $8.00.

View Our Latest Report on Quantum Biopharma

Quantum Biopharma Stock Down 9.6%

Shares of NASDAQ QNTM traded down $0.17 during trading on Friday, reaching $1.61. The company had a trading volume of 86,433 shares, compared to its average volume of 100,060. Quantum Biopharma has a 12-month low of $1.60 and a 12-month high of $12.42. The business’s 50-day moving average is $2.90 and its 200 day moving average is $3.68. The stock has a market cap of $13.02 million, a PE ratio of -0.37 and a beta of 0.51.

Quantum Biopharma (NASDAQ:QNTM – Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.44.

Institutional Investors Weigh In On Quantum Biopharma

A hedge fund recently raised its position in Quantum Biopharma stock. Steward Partners Investment Advisory LLC grew its position in shares of Quantum Biopharma Ltd. (NASDAQ:QNTM – Free Report) by 46.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 40,942 shares of the company’s stock after buying an additional 13,061 shares during the quarter. Steward Partners Investment Advisory LLC owned 0.51% of Quantum Biopharma worth $147,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 1.24% of the stock is owned by institutional investors.

Quantum Biopharma Company Profile

(Get Free Report)

Quantum BioPharma Ltd. is a Canadian biopharmaceutical company focused on developing treatments for neurodegenerative and other challenging medical conditions. The company was formerly known as FSD Pharma and adopted its current name in 2024. Its lead research program is Lucid-MS, an investigational drug candidate being developed for multiple sclerosis. The company describes the program as targeting myelin degradation, a process associated with the disease. Lucid-MS is still under development and is not an approved treatment.

Recommended Stories

Receive News & Ratings for Quantum Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quantum Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.